D46.2 Refractory anemia with excess of blasts [RAEB]

Name of the Condition

• Refractory anemia with excess of blasts [RAEB]

Summary

Refractory anemia with excess of blasts (RAEB) is a subtype of myelodysplastic syndrome (MDS) characterized by ineffective blood cell production in the bone marrow, leading to low blood cell counts (cytopenias) and abnormal cell development. The condition is termed "refractory" because it does not respond to standard treatments for anemia. RAEB is distinguished by the presence of an increased number of immature blood cells (blasts) in the bone marrow and blood, and it carries a higher risk of progressing to acute myeloid leukemia (AML) compared to other MDS subtypes.

Causes

The exact cause of RAEB is often unknown. It may involve genetic mutations that disrupt normal blood cell production. Other factors can include previous chemotherapy or radiation therapy, exposure to certain chemicals (e.g., benzene), and rarely, inherited bone marrow failure syndromes.

Risk Factors

• Age (most common in individuals over 60)
• Previous cancer treatment with chemotherapy or radiation
• Exposure to industrial chemicals like benzene
• Family history of MDS or other blood disorders
• Certain genetic conditions (e.g., Fanconi anemia)

Symptoms

• Fatigue or weakness
• Frequent infections
• Easy or unexplained bruising or bleeding
• Shortness of breath
• Pale skin
• Unexplained weight loss

Diagnosis

Diagnosis involves a complete blood count (CBC) to identify cytopenias, followed by a bone marrow biopsy to assess cell dysplasia and blast percentage. Cytogenetic analysis may be performed to detect chromosomal abnormalities, and additional tests (e.g., flow cytometry) may help evaluate blast populations.

Treatment Options

Treatment depends on the severity of symptoms, age, and overall health. Options may include supportive care (e.g., blood transfusions, growth factors), chemotherapy, or stem cell transplantation for eligible patients. Clinical trials may be considered for advanced cases.

Prognosis and Follow-Up

Prognosis varies based on blast count, cytogenetic findings, and patient factors. Regular monitoring of blood counts and bone marrow status is essential to detect progression to AML. Follow-up care focuses on managing symptoms and complications.

Complications

• Progression to acute myeloid leukemia (AML)
• Severe anemia requiring transfusions
• Increased risk of infections due to low white blood cell counts
• Bleeding complications from low platelet counts

Lifestyle & Prevention

• Avoid exposure to known toxins (e.g., benzene)
• Maintain a balanced diet to support overall health
• Practice good hygiene to reduce infection risk
• Follow up regularly with healthcare providers for monitoring

When to Seek Professional Help

Seek medical attention if experiencing persistent fatigue, unexplained bruising or bleeding, frequent infections, or shortness of breath. Prompt evaluation is important for early diagnosis and management.

Tips for Medical Coders

Document the blast percentage in bone marrow or blood, as this is critical for coding accuracy. Include details on cytogenetic findings and any prior treatments (e.g., chemotherapy) that may influence the diagnosis. Ensure documentation supports the specific MDS subtype and excludes other conditions with similar presentations.